We are live on ! Find out more
FBIOP icon

Fortress Biotech 9.375% Series A Preferred Stock
FBIOP

3 hedge funds and large institutions have $7.51M invested in Fortress Biotech 9.375% Series A Preferred Stock in 2021 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $6.95M → $7.51M (+$555K)

0% more funds holding

Funds holding: 3 → 3 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.08% less ownership

Funds ownership: 8.52% → 8.43% (-0.08%)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SAM
Shikiar Asset Management
New York
+$79.1K

Top Sellers

Rank Fund Capital Flow
1
UIC
Uniplan Investment Counsel
Wisconsin
-$152K
Name Holding Trade Value Shares
Change 		Change in
Stake
UIC
1
Uniplan Investment Counsel
Wisconsin
$4.28M -$152K -5,949 -3%
SAM
2
Shikiar Asset Management
New York
$3.23M +$79.1K +3,100 +3%
PCG
3
Private Capital Group
Connecticut
$4K – – –

FBIOP Hedge Fund Activity: Q2 2021 in Review

3 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q2 2021, worth a combined $7.51M — up 8% from $6.95M a quarter earlier.

Fund positioning in FBIOP was balanced in Q2 2021: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Shikiar Asset Management, adding an estimated $79.1K. The largest seller was Uniplan Investment Counsel, cutting an estimated $152K.

  • 3 institutional investors held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q2 2021, unchanged from Q1 2021.
  • Funds reported $7.51M of Fortress Biotech 9.375% Series A Preferred Stock stock for Q2 2021, up 8% quarter-over-quarter.
  • 0 funds opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q2 2021 and 0 closed out.
  • The largest Fortress Biotech 9.375% Series A Preferred Stock buyer in Q2 2021 was Shikiar Asset Management, an estimated $79.1K added.
  • The largest Fortress Biotech 9.375% Series A Preferred Stock seller in Q2 2021 was Uniplan Investment Counsel, an estimated $152K sold.

Based on aggregated 13F filings for Q2 2021.